Gastrointestinal Stromal Tumors
Information
- Disease name
- Gastrointestinal Stromal Tumors
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05697107 | Active, not recruiting | Ripretinib in Chinese Patients With Advanced GIST: a Real World Study | May 20, 2021 | December 30, 2023 | |
| NCT04825574 | Active, not recruiting | Phase 4 | Study for Patients Previously Treated in Avapritinib Clinical Trials | May 21, 2021 | August 1, 2025 |
| NCT03673501 | Active, not recruiting | Phase 3 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | February 8, 2019 | December 2024 |
| NCT03556384 | Active, not recruiting | Phase 2 | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) | September 12, 2018 | June 2025 |
| NCT00756509 | Active, not recruiting | Phase 4 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | August 29, 2008 | December 31, 2024 |
| NCT01541709 | Active, not recruiting | Phase 2 | Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI | March 2012 | December 31, 2024 |
| NCT00293124 | Completed | Phase 3 | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | March 2004 | July 2008 |
| NCT00385203 | Completed | Phase 2 | The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). | September 2006 | December 2009 |
| NCT00441155 | Completed | Phase 1 | Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib | November 2006 | January 2011 |
| NCT00444795 | Completed | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene | May 2007 | March 2015 | |
| NCT00455559 | Completed | Phase 2 | Ph II Study of Perifosine Plus Gleevec for Patients With GIST | August 2006 | October 2011 |
| NCT00457743 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) | January 2005 | August 2008 |
| NCT00471328 | Completed | Phase 3 | Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib | March 2007 | June 2011 |
| NCT00500188 | Completed | Phase 2 | Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST | July 2003 | July 2011 |
| NCT00507273 | Completed | Gastrointestinal Stromal Tumors (GIST) Registry | August 2005 | December 2010 | |
| NCT00564265 | Completed | Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo | January 2008 | August 2008 | |
| NCT00570635 | Completed | Phase 2 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | December 2007 | May 2009 |
| NCT00716820 | Completed | Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). | April 2008 | September 2016 | |
| NCT00718211 | Completed | A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore | May 2006 | ||
| NCT00718562 | Completed | Phase 2 | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib | September 2008 | July 2013 |
| NCT01091207 | Completed | Phase 2 | Sorafenib for Imatinib/Sunitinib-failed GIST | November 2009 | August 2011 |
| NCT00137449 | Completed | Phase 2 | Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor | September 2005 | April 2008 |
| NCT00171977 | Completed | Phase 4 | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) | July 2004 | |
| NCT00237172 | Completed | Phase 2 | Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) | September 2002 | |
| NCT00276302 | Completed | Phase 1 | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) | December 2005 | November 2010 |
| NCT00278876 | Completed | Phase 2 | Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation | April 2005 | March 2011 |
| NCT00877045 | Completed | Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | January 2008 | February 2009 | |
| NCT00976612 | Completed | Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK | January 2009 | December 2011 | |
| NCT00135005 | Completed | Phase 1 | Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) | August 2005 | November 2006 |
| NCT01114087 | Completed | N/A | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility | October 2008 | May 2009 |
| NCT01151852 | Completed | Phase 3 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | June 2010 | March 2013 |
| NCT01172548 | Completed | Phase 2 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) | August 2008 | March 2014 |
| NCT01265810 | Completed | Phase 3 | Caphosol in Oral Mucositis Due to Targeted Therapy | November 2011 | October 2015 |
| NCT01265979 | Completed | WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib | January 2011 | September 2011 | |
| NCT01270984 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects | November 2010 | December 2010 |
| NCT01271712 | Completed | Phase 3 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) | January 4, 2011 | April 15, 2019 |
| NCT01275222 | Completed | Phase 1/Phase 2 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | November 13, 2002 | September 3, 2008 |
| NCT01289028 | Completed | Phase 3 | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. | November 2008 | July 2014 |
| NCT01396148 | Completed | Phase 2 | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | June 2012 | August 2017 |
| NCT01421680 | Completed | N/A | The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients | August 2011 | December 2013 |
| NCT01440959 | Completed | Phase 2 | Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | September 2011 | March 2013 |
| NCT01462994 | Completed | Phase 3 | Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | November 2011 | March 2016 |
| NCT01478373 | Completed | Phase 2 | Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | January 2012 | July 2014 |
| NCT01483014 | Completed | Phase 2 | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) | June 2008 | January 2012 |
| NCT01524848 | Completed | Phase 2 | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | February 2012 | November 2016 |
| NCT01694277 | Completed | Phase 3 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | April 2012 | December 2020 |
| NCT01863745 | Completed | Phase 2 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | June 25, 2013 | October 2, 2023 |
| NCT01933958 | Completed | Regorafenib Post-marketing Surveillance in Japan | September 4, 2013 | October 29, 2021 | |
| NCT02171286 | Completed | The Oncopanel Pilot (TOP) Study | October 2014 | March 2017 | |
| NCT02260505 | Completed | Phase 3 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | December 24, 2014 | December 2023 |
| NCT02401815 | Completed | Phase 1/Phase 2 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | March 6, 2015 | May 11, 2020 |
| NCT02571036 | Completed | Phase 1 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | November 2015 | April 29, 2022 |
| NCT02607332 | Completed | Phase 2 | Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | November 2015 | January 2018 |
| NCT02638766 | Completed | Phase 2 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST | November 2015 | August 31, 2021 |
| NCT02662478 | Completed | Laparoscopic Resection of Large Gastric Stromal Tumors | June 2008 | February 2016 | |
| NCT02800330 | Completed | Phase 4 | The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib | May 2016 | February 2018 |
| NCT02931929 | Completed | Phase 1/Phase 2 | MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT | November 28, 2016 | April 9, 2019 |
| NCT03353753 | Completed | Phase 3 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies | February 27, 2018 | May 11, 2022 |
| NCT03609424 | Completed | Phase 1/Phase 2 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | February 14, 2019 | November 11, 2021 |
| NCT04254939 | Completed | Phase 1/Phase 2 | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | August 15, 2019 | April 11, 2023 |
| NCT04282980 | Completed | Phase 2 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | April 23, 2020 | August 23, 2022 |
| NCT04343456 | Completed | Salvage Surgery for Patients With Metastatic GIST With Rego | January 1, 2014 | February 28, 2020 | |
| NCT04908176 | Completed | Phase 1 | A Drug-drug Interaction Study of Avapritinib and Midazolam | August 24, 2022 | April 12, 2024 |
| NCT05400018 | Completed | Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients | November 20, 2020 | February 25, 2021 | |
| NCT05565066 | Completed | A Real-world Comparison of FNB and FNA in IHC-required Lesions. | December 1, 2014 | October 31, 2022 | |
| NCT05800106 | Completed | Phase 1 | A Bioequivalence Study of Sunitinib Malate Capsules. | December 4, 2018 | January 12, 2019 |
| NCT01689376 | No longer available | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) | |||
| NCT01646593 | No longer available | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy | |||
| NCT06431451 | Not yet recruiting | The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients With Advanced GISTs | June 1, 2024 | December 2025 | |
| NCT04825470 | Not yet recruiting | N/A | Liver Transplantation for Unresectable GIST Liver Metastases | May 2022 | December 2025 |
| NCT06087263 | Not yet recruiting | Phase 2 | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | April 30, 2024 | July 1, 2034 |
| NCT06208748 | Not yet recruiting | Phase 2 | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | June 2024 | June 2027 |
| NCT06326346 | Not yet recruiting | Phase 2 | GIST Oral Paclitaxel(Liporaxel) | June 1, 2024 | March 31, 2027 |
| NCT05461664 | Not yet recruiting | Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA | July 10, 2022 | August 31, 2024 | |
| NCT05464875 | Not yet recruiting | A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors | July 9, 2022 | August 31, 2024 | |
| NCT03944304 | Recruiting | Phase 2 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | May 27, 2019 | November 30, 2025 |
| NCT05665868 | Recruiting | N/A | Study on Integrated Nursing Strategy for Patients With Gastrointestinal Stromal Tumors After Targeted Therapy | April 1, 2022 | April 1, 2025 |
| NCT05751733 | Recruiting | N/A | Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | February 1, 2023 | January 1, 2027 |
| NCT03602092 | Recruiting | Observational Registry Data on GIST Patients | October 16, 2018 | December 31, 2025 | |
| NCT05661643 | Recruiting | Phase 2 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST | June 28, 2023 | December 31, 2027 |
| NCT04181970 | Recruiting | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK | June 30, 2019 | September 30, 2025 | |
| NCT05867901 | Recruiting | Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence | June 1, 2023 | June 30, 2027 | |
| NCT05905887 | Recruiting | Phase 2 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | September 6, 2023 | December 31, 2026 |
| NCT05938309 | Recruiting | A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors | May 1, 2023 | May 1, 2028 | |
| NCT04584008 | Recruiting | N/A | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | September 23, 2020 | February 2024 |
| NCT05197933 | Recruiting | N/A | Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach | October 1, 2020 | September 30, 2025 |
| NCT05245968 | Recruiting | Phase 1 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | December 1, 2021 | December 2025 |
| NCT05366816 | Recruiting | Phase 2 | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | October 17, 2023 | December 2028 |
| NCT05381753 | Recruiting | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | August 29, 2022 | October 2025 | |
| NCT05385549 | Recruiting | Phase 2 | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | September 7, 2022 | April 30, 2030 |
| NCT05408897 | Recruiting | Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD | January 1, 2022 | April 2028 | |
| NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
| NCT05440357 | Recruiting | Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study | July 1, 2022 | September 30, 2024 | |
| NCT05493215 | Recruiting | Phase 2 | Imatinib TDM in GIST | March 26, 2024 | December 2025 |
| NCT05500391 | Recruiting | Phase 2 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring | February 28, 2024 | October 2029 |
| NCT04714983 | Suspended | Phase 1 | DNX-2440 for Resectable Colorectal Liver Metastasis | February 15, 2021 | December 31, 2026 |
| NCT00688766 | Terminated | Phase 3 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | August 2008 | May 2009 |
| NCT00585221 | Terminated | Phase 2 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | July 2007 | July 2009 |
| NCT00751036 | Terminated | Phase 3 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg | June 2009 | August 2012 |
| NCT02232620 | Terminated | Phase 2 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | March 13, 2017 | July 25, 2017 |
| NCT00782834 | Terminated | Phase 2 | Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) | July 2008 | October 2009 |
| NCT04000529 | Terminated | Phase 1 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | July 30, 2019 | January 15, 2024 |
| NCT03291054 | Terminated | Phase 2 | Epacadostat and Pembrolizumab in Patients With GIST | February 28, 2018 | August 19, 2020 |
| NCT00812240 | Terminated | Phase 3 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | January 2009 | July 2018 |
| NCT01031628 | Terminated | Phase 3 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | January 2010 | June 2011 |
| NCT04276415 | Terminated | Phase 1 | DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) | May 8, 2020 | March 11, 2022 |
| NCT03165721 | Terminated | Phase 2 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | August 16, 2017 | February 24, 2020 |
| NCT04409223 | Terminated | Phase 3 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | September 12, 2020 | March 25, 2022 |
| NCT02488746 | Terminated | Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) | March 2015 | September 2018 | |
| NCT03092128 | Unknown status | A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment | June 2014 | June 2020 | |
| NCT03601234 | Unknown status | N/A | Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors | April 16, 2018 | December 30, 2019 |
| NCT04258956 | Unknown status | Phase 2 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy | April 30, 2019 | April 30, 2023 |
| NCT03862768 | Unknown status | N/A | Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment | July 2019 | December 2021 |
| NCT01178307 | Unknown status | Symptom Inventory for Gastrointestinal Stromal Tumors | July 29, 2010 | July 31, 2020 | |
| NCT01381822 | Unknown status | Phase 1 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | June 2011 | June 2014 |
| NCT05001204 | Unknown status | Early Phase 1 | 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor | May 1, 2021 | August 31, 2022 |
| NCT00290485 | Unknown status | Phase 2 | Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) | August 2005 | |
| NCT05132738 | Unknown status | N/A | Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | August 1, 2021 | November 30, 2023 |
| NCT02866045 | Unknown status | Phase 3 | EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs | May 2016 | December 2018 |
| NCT04106024 | Unknown status | Phase 2 | Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial | October 23, 2018 | April 30, 2020 |
| NCT05080621 | Withdrawn | Phase 1/Phase 2 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | November 2021 | May 2027 |
| NCT04811833 | Withdrawn | Gastrointestinal Anastomosis Using MonoPlus® Suture | July 2022 | December 2023 | |
| NCT02342600 | Withdrawn | Phase 2 | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | January 2017 | |
| NCT02268435 | Withdrawn | Phase 1 | Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors | March 2015 | November 2016 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D046152